December 20, 2017 / 6:33 AM / a month ago

BRIEF-4SC Gets Pediatric Investigation Plan Waiver For Resminostat In CTCL From European Medicines Agency

Dec 20 (Reuters) - 4SC AG:

* DGAP-NEWS: 4SC RECEIVES PEDIATRIC INVESTIGATION PLAN WAIVER FOR RESMINOSTAT IN CTCL FROM THE EUROPEAN MEDICINES AGENCY

* RESMINOSTAT BEING EVALUATED AS MAINTENANCE THERAPY IN ADVANCED-STAGE CTCL PATIENTS IN PIVOTAL RESMAIN STUDY

* TOP-LINE RESULTS ARE EXPECTED TO BE AVAILABLE IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below